La chaîne d'options affiche les données clés des options sur actions de Galapagos à différents prix d'exercice et dates d'expiration. Les traders utilisent ces informations pour analyser les transactions potentielles et évaluer le sentiment du marché pour Galapagos..

Galapagos (NASDAQ:GLPG) Stock, Chaîne d'Options

Galapagos

Galapagos NV is a fully integrated biotechnology company with operations in Europe and the United States, dedicated to developing medicines focusing on oncology and immunology. The group focuses on unmet medical needs, it synergizes compelling science, technology, and collaborative approaches to create a deep pipeline of medicines. Its clinical pipeline includes: GLPG5101, a CD19 CAR-T product candidate decentralized manufactured, currently in Phase 1/2 in rrNHL; GLPG5301, a BCMA CAR-T product candidate decentralized manufactured, currently in Phase 1 in rrMM; and GLPG3667, a TYK2 inhibitor currently in Phase 2 clinical trial in DM and SLE. It derives maximum revenue from the United States of America.

Galapagos NV - American Depositary Shares

Galapagos NV

Oruka Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ORKA#NASDAQ">ORKA</a>) reported quarterly losses of $(0.40) per share which beat the analyst consensus estimate of $(0.52) by 23.08 percent. This is a 81.9 percent increase over losses of $(2.21) per share from the same period last year.

Earnings

Earnings Beats

News

ORKA

Oruka Therapeutics Q1 EPS $(0.40) Beats $(0.52) Estimate

Jade Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JBIO#NASDAQ">JBIO</a>) reported quarterly losses of $(12.10) per share which missed the analyst consensus estimate of $(1.74) by 595.4 percent.

Earnings Misses

JBIO

Jade Biosciences Q1 EPS $(12.10) Misses $(1.74) Estimate

Contango Ore (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/CTGO#AMEX">CTGO</a>) reported quarterly losses of $(1.88) per share which missed the analyst consensus estimate of $(0.21) by 795.24 percent. This is a 12.15 percent increase over losses of $(2.14) per share from the same period last year.

CTGO

Contango Ore Q1 EPS $(1.88) Misses $(0.21) Estimate

Aardvark Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AARD#NASDAQ">AARD</a>) reported quarterly losses of $(0.71) per share. This is a 29.09 percent decrease over losses of $(0.55) per share from the same period last year.

AARD

Aardvark Therapeutics Q1 EPS $(0.71) Down From $(0.55) YoY

Enpro Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NPO#NYSE">NPO</a>) today announced the pricing of its previously announced offering of senior notes due 2033 (the "Senior Notes"). The face value of the Senior Notes is $450 million with an annual interest rate of 6.125%. The Senior Notes were priced at 100.0% of the face value. The offer was made in the United States to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"), and to non-U.S. persons in reliance on Regulation S under the Securities Act. The Senior Notes offering is expected to close on May 29, 2025.
Enpro intends to use the net proceeds from the offering to fund the redemption of all of its outstanding 5.75% senior notes due 2026 (the "Outstanding Notes"), to repay a portion of the borrowings under its senior secured revolving credit facility used to fund the repayment on April 9, 2025 of all of its then-outstanding term loans under its senior secured credit facility, and to pay fees and expenses in connection with the offering. The conditional redemption of the Outstanding Notes was announced by Enpro on May 13, 2025.

Offerings

Enpro Inc. Prices Offering Of $450M 6.125% Senior Notes Due 2033

Enveric Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENVB#NASDAQ">ENVB</a>) reported quarterly losses of $(1.22) per share. This is a 86.75 percent increase over losses of $(9.21) per share from the same period last year.

ENVB

Enveric Biosciences Q1 EPS $(1.22) Up From $(9.21) YoY

Empire Petroleum (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/EP#AMEX">EP</a>) reported quarterly losses of $(0.13) per share. This is a 13.33 percent increase over losses of $(0.15) per share from the same period last year. The company reported $9.00 million in sales this quarter. This is a 4.10 percent decrease over sales of $9.39 million the same period last year.

Empire Petroleum Q1 Adj. EPS $(0.13) Up From $(0.15) YoY, Sales $9.00M Down From $9.39M YoY

Blaize Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BZAI#NASDAQ">BZAI</a>) sees Q2 sales of $1.500 million-$1.700 million vs $1.52 million analyst estimate.

Guidance

BZAI

Blaize Holdings Sees Q2 Sales $1.500M-$1.700M vs $1.52M Est

Blaize Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BZAI#NASDAQ">BZAI</a>) affirms FY2025 sales outlook from $19.00 million-$50.00 million to $19.00 million-$50.00 million.

Blaize Holdings Affirms FY2025 Sales Guidance of $19.00M-$50.00M

MetaVia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MTVA#NASDAQ">MTVA</a>) reported quarterly losses of $(0.36) per share which beat the analyst consensus estimate of $(0.51) by 29.41 percent. This is a 72.73 percent increase over losses of $(1.32) per share from the same period last year.

MTVA

MetaVia Q1 EPS $(0.36) Beats $(0.51) Estimate

Boxlight (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BOXL#NASDAQ">BOXL</a>) reported quarterly losses of $(1.41) per share. This is a 62.89 percent increase over losses of $(3.80) per share from the same period last year. The company reported $22.40 million in sales this quarter. This is a 39.61 percent decrease over sales of $37.09 million the same period last year.

BOXL

Boxlight Q1 EPS $(1.41) Up From $(3.80) YoY, Sales $22.40M Down From $37.09M YoY

Vroom (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRM#NASDAQ">VRM</a>) reported quarterly losses of $(1.23) per share. This is a 96.74 percent increase over losses of $(37.68) per share from the same period last year. The company reported $36.20 million in sales this quarter. This is a 3.78 percent increase over sales of $34.88 million the same period last year.

Vroom Q1 EPS $(1.23) Up From $(37.68) YoY, Sales $36.20M Up From $34.88M YoY

CSWC

CORRECTION: Capital Southwest Q4 EPS $0.54 Misses $0.62 Estimate, Sales $52.41M Miss $52.71M Estimate

Steris (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STE#NYSE">STE</a>) is looking for FY2026 Adj EPS of $9.90-$10.15 vs $9.87 analyst estimate..

Steris Sees FY2026 expects reported revenue from continuing operations to increase 6-7%.

Castor Maritime (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTRM#NASDAQ">CTRM</a>) reported quarterly losses of $(1.24) per share. This is a 212.73 percent decrease over earnings of $1.10 per share from the same period last year. The company reported $16.16 million in sales this quarter. This is a 38.69 percent decrease over sales of $26.36 million the same period last year.

CTRM

Castor Maritime Q4 EPS $(1.24) Down From $1.10 YoY, Sales $16.16M Down From $26.36M YoY

Red Cat Holdings Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RCAT#NASDAQ">RCAT</a>) reported first-quarter financial results after the market close on Wednesday. Here&#8217;s a rundown of the <a href="https://www.benzinga.com/pressreleases/25/05/g45419266/red-cat-reports-financial-results-for-first-quarter-2025-and-provides-corporate-update">drone technology company&#8217;s report</a>.
Q1 Earnings: Red Cat reported first-quarter revenue of $1.63 million, missing <a href="https://www.benzinga.com/quote/rcat/earnings" target="_blank" rel="noreferrer noopener">analyst estimates</a> of $3.85 million. The company reported a first-quarter loss of 27 cents per share, missing analyst estimates for a loss of eight cents per share, according to <a href="http://pro.benzinga.com/" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>.
Red Cat said it expects its partnership with Palantir Technologies will reduce costs and improve margins moving forward.
Red Cat ended the first quarter with $9.3 million in cash and accounts receivable. The company noted that it also closed on $30 million of funding subsequent to the quarter&#8217;s end.
&#8220;Red Cat&#8217;s momentum continues to build as we execute on our strategy to deliver advanced, AI-enabled unmanned systems across air, land, and sea,&#8221; said&nbsp;Jeff Thompson, CEO of Red Cat.
&#8220;Our partnership with Palantir to deploy Warp Speed is optimizing our manufacturing and cost efficiency, while our expansion into maritime autonomy with Unmanned Surface Vessels significantly expands our Family of Systems.&#8221;
Guidance: Red Cat affirmed its full-year 2025 revenue guidance of $80 million to $120 million versus estimates of $80.17 million. Here&#8217;s a breakdown of guidance by category:
<ul class="wp-block-list">
<li>SRR-related Black Widow revenue: $25 to $65 million</li>
</ul>
<ul class="wp-block-list">
<li>Non-SRR Black Widow revenue: $25 million</li>
</ul>
<ul class="wp-block-list">
<li>Edge 130 revenue: $25 million</li>
</ul>
<ul class="wp-block-list">
<li>Fang FPV revenue: $5 million</li>
</ul>
Red Cat executives will further discuss details from the quarter on a call with investors and analysts at 4:30 p.m. ET.
RCAT Price Action: <a href="http://benzinga.com/quote/rcat" target="_blank" rel="noreferrer noopener">Red Cat Holdings shares</a> were down 5.26% in after-hours, trading at $6.30 at the time of publication on Wednesday, per <a href="http://pro.benzinga.com/" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/technicals/25/05/45408452/stock-of-the-day-palantir-breaks-out-sell-news-rally">Stock Of The Day: Palantir Breaks Out As Classic &#8216;Sell the News&#8217; Sets Up Rally</a></li>
</ul>
Photo: <a href="https://www.shutterstock.com/g/MacroEcon">MacroEcon</a>/Shutterstock.

After-Hours Center

Movers

RCAT

Red Cat Holdings Q1 Earnings: Revenue, EPS Miss Estimates, Drone Maker Affirms FY25 Guidance, Highlights Palantir Partnership, Shares Slide

WIIM

USIO

Usio shares are trading lower after the company reported mixed Q1 financial results.

Edesa Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EDSA#NASDAQ">EDSA</a>) reported quarterly losses of $(0.30) per share which missed the analyst consensus estimate of $(0.29) by 3.45 percent. This is a 48.28 percent increase over losses of $(0.58) per share from the same period last year.

EDSA

Edesa Biotech Q2 EPS $(0.30) Misses $(0.29) Estimate

SILO

Silo Pharma shares are trading lower. The company announced  it has engaged Veloxity Labs for bioanalysis supporting the ongoing investigational new drug-enabling GLP-compliant toxicology and toxicokinetics study of SPC-15.

Enliven Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ELVN#NASDAQ">ELVN</a>) reported quarterly losses of $(0.57) per share which missed the analyst consensus estimate of $(0.49) by 16.33 percent. This is a 5.56 percent decrease over losses of $(0.54) per share from the same period last year.

ELVN

Enliven Therapeutics Q1 EPS $(0.57) Misses $(0.49) Estimate

Press Releases

Galapagos to Unlock Shareholder Value by Declaring its Intent to Separate into Two Publicly Traded Entities

Galapagos Reports Full Year 2024 Results and Provides Fourth Quarter Business Update

Galapagos receives transparency notification and 13D filing from Tang Capital

Galapagos to Present at Upcoming Investor Conferences

Galapagos Publishes 2024 Annual Report and Announces Annual Shareholders' Meeting

Galapagos Announces Departure of Thad Huston, CFO and COO, as of August 1, 2025

Galapagos Announces Executive Leadership Updates

Galapagos Reports First Quarter 2025 Financial Results, Recent Business Highlights and Near-Term Catalysts

Galapagos Announces Strategic Update on Proposed Separation, Executive Leadership Transition and Board Changes

Galapagos Announces Oral Presentations at EHA and ICML 2025 Featuring Promising New Data from ATALANTA-1 study of Investigational CAR-T Candidate GLPG5101

Comments

Galapagos

Galapagos (GLPG) Options

Galapagos (NASDAQ:GLPG) Stock, Chaîne d'Options

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL